Subscribe to the BioNews newsletter for free

Advanced Search

Search for

Like the Progress Educational Trust on Facebook

The Fertility Show, Manchester Central, 24-25 March 2018


Three genomics start-ups get Illumina funding boost

20 October 2014

By Sean Byrne

Appeared in BioNews 776

Illumina has announced the first three companies in its Accelerator Programme, designed to help genomics start-ups as other sources of funding grow scarce.

The six-month programme gives the companies access to and credit for Illumina's sequencing technology, lab space in the San Francisco Bay area and a $100,000 loan.

The winning companies, chosen from 30 applicants, are Encoded Genomics, EpiBiome, and Xcell Biosciences.

Dr Mostafa Ronaghi, Illumina's senior vice president and chief technology officer, said the company was 'very excited to work with these entrepreneurs to help them expand the next-generation sequencing market'.

The companies work in diverse areas: Encoded Genomics analyses the human genome for information which may be of use in drug development; EpiBiome focuses on agriculture, hoping to develop a virus to fight bacterial infections in dairy cattle; and Xcell Biosciences are developing a tool to help grow specific cells, including cancer and immune cells, from a patient's blood.

Illumina's move towards funding early-stage companies, in addition to continuing their own research, may be, according to Nature magazine, 'a smart way for Illumina to boost the size of its own potential market'.

'They have this amazing technology, and they're thinking, "How do we accelerate its adoption?"' Deniz Kural, chief executive of Seven Bridges Genomics, a US bioinformatics company, told the magazine. 'It's hard for any one company to explore all these markets.'

Illumina's programme also comes at a time when software for genomic research is developing faster than the hardware that is the company's backbone.

'This is partly Illumina's strategy of staying relevant even when the focus shifts from hardware to software,' Kural told Nature.

Illumina is now accepting applications for its spring 2015 accelerator programme.

Illumina (press release) | 15 October 2014
Xconomy | 15 October 2014
Nature | 15 October 2014
Genetic Engineering and Biotechnology News | 15 October 2014


27 November 2017 - by Dr Rachel Brown 
The UK Patents Court has ruled that two separate non-invasive prenatal tests infringe patents licensed by the US firm Illumina...
29 February 2016 - by Ryan Ross 
The California-based genome-sequencing company Illumina has accused UK rival Oxford Nanopore Technologies of violating its intellectual property rights...

26 August 2014 - by Dr Molly Godfrey 
The DNA sequencing company Illumina have announced collaborations with three major pharmaceutical companies - AstraZeneca, Sanofi and Johnson & Johnson - to develop a single test for several gene mutations in cancer...
17 March 2014 - by Chee Hoe Low 
Genome sequencing technology struggles to capture the complete genome accurately and reliably, a small study has found...
20 January 2014 - by Dr Rachael Panizzo 
The $1,000 genome may have arrived, an achievement which would mark a significant milestone in the application of genetic science...
16 July 2012 - by Daryl Ramai 
Technology that relies on less DNA to more accurately sequence people's genomes has been unveiled by a US biotech company...

Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions

- click here to enquire about using this story.

Published by the Progress Educational Trust
Advertise your products and services HERE - click for further details

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation